Drug Trial Radar · NCT05543330
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
116
Planned (sponsor's estimate)
Start
Sep 30, 2022
Primary completion
Sep 15, 2026
Study completion Dec 15, 2026
Sponsor
- Lead sponsor
- Wuhan YZY Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.
Conditions
- Malignant Pleural Effusions
- NSCLC Stage IV
Interventions
M701 pleural infusionDrug
M701 pleural infusion on Days 1,4,7 and 10.
Pleural drainageProcedure
Pleural effusion drainage via Ultra-sound guidance on Day 1.
Cisplatin pleural infusionDrug
Cisplatin pleural infusion (30-50mg/m2) on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLTs)Time frame: From the time of the first dose (Day 1) until the forth dosing (Day 28)
- Incidence of AEsTime frame: From the start of administration to the end of the study or 28 days after the administration is stopped
- Puncture-free survival (PuFS)Time frame: The time from removing the thoracic drainage tube after last intrapleural infusion to the time when re-drainage is required or death, assessed up to 12 months after enrollment or randomization.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.